Eugia Pharma Receives USFDA Approval for Cyclophosphamide Injection
Published: September 01, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cyclophosphamide Injection 500 mg/2.5 mL and 1 g/5 mL vials.
Eugia’s product will be available in ready-to-use (RTU) injection preparation. The product shall be launched in the US market through its subsidiary Eugia in the near term and will be manufactured in Eugia’s manufacturing facility in India.
- Eugia’s Cyclophosphamide Injection is indicated for:
- Malignant lymphomas
- Multiple myeloma
- Leukemias
- Mycosis fungoides (advanced disease)
- Neuroblastoma (disseminated disease)
- Adenocarcinoma of the ovary
- Retinoblastoma
- Carcinoma of the breast